Protecting our Pharmaceutical Supply Chain from China Act of 2022
Latest action · Mar 28, 2022 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedMar 17, 2022
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Protecting our Pharmaceutical Supply Chain from China Act of 2022
This bill requires the federal government to maintain a registry of certain foreign-sourced drugs, prohibits federal health care programs from purchasing drugs containing ingredients manufactured in China, requires drugs to be labeled for country of origin, and offers domestic manufacturing facility tax incentives.
The Food and Drug Administration shall maintain (1) a list of foreign-sourced drugs and active ingredients that are critical for consumer health and safety, and (2) another list identifying such drugs that are produced exclusively in China or use ingredients produced in China.
The bill phases in a restriction on federal health care programs purchasing drugs with active ingredients manufactured in China. By January 1, 2024, such programs may not purchase a drug with any active ingredients from China. The Department of Health and Human Services may issue a waiver for an agency or program that is unable to meet this requirement, but no waiver may apply to drugs purchased in or after 2026.
Each drug must have labeling listing the country of origin of each active ingredient, and a drug without this labeling shall be deemed misbranded.
The bill allows 100% tax expensing for qualified pharmaceutical and medical device manufacturing property placed in service between 2020 and 2026.
Cosponsors 8
Members who signed on, in the order they did. Signatures ran from Mar 17, 2022 to Jun 23, 2022; 6 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-FL | Bill Posey | Original | Mar 17, 2022 |
| R-NY | Elise M. Stefanik | Original | Mar 17, 2022 |
| D-NJ | Jefferson Van Drew | Original | Mar 17, 2022 |
| R-WY | Liz Cheney | Original | Mar 17, 2022 |
| R-NC | Ted Budd | Original | Mar 17, 2022 |
| R-MO | Vicky Hartzler | Original | Mar 17, 2022 |
| R-TN | Diana Harshbarger | May 11, 2022 | |
| R-TX | Brian Babin | Jun 23, 2022 |
Committees 4
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Mar 17, 2022 |
| Health Subcommittee | Referred Mar 18, 2022 | |
| House | Ways and Means Committee | Referred Mar 17, 2022 |
| House | Veterans' Affairs Committee | Referred Mar 17, 2022 |
| Health Subcommittee | Referred Mar 28, 2022 | |
| House | Armed Services Committee | Referred Mar 17, 2022 |
Actions 4
Everything that happened, newest first.
- Mar 28, 2022Referred to the Subcommittee on Health.
- Mar 18, 2022Referred to the Subcommittee on Health.
- Mar 17, 2022Introduced in House
- Mar 17, 2022Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Veterans' Affairs, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 168, no. 48, March 17, 2022, page H3828.
Related bills 2
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 2495 | Protecting our Pharmaceutical Supply Chain from China Act of 2021 | Related bill | Jul 28, 2021 |
| S 3401 | ABC Safe Drug Act | Related bill | Dec 15, 2021 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To require the Secretary of Health and Human Services to maintain a list of the country of origin of all drugs marketed in the United States, to ban the use of Federal funds for the purchase of drugs manufactured in the People's Republic of China, and for other purposes.
- Short Title(s) as Introduced
- Protecting our Pharmaceutical Supply Chain from China Act of 2022
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Asia
- Business expenses
- China
- Drug safety, medical device, and laboratory regulation
- Government information and archives
- Health
- Health care costs and insurance
- Health programs administration and funding
- Health technology, devices, supplies
- Income tax deductions
- Manufacturing
- Military medicine
- Military procurement, research, weapons development
- Prescription drugs
- Public contracts and procurement
- Trade restrictions
- Veterans' medical care
Text 1
Each version as it was printed, newest first.
- Mar 17, 2022Introduced in House
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
